Alphatec : Investor Deck - January 2021

REVOLUTIONIZING THE APPROACH TO SPINE SURGERY

J a n u a r y 2 0 2 1

FORWARD LOOKING STATEMENTS

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described therein. Forward-looking statements include references to the impact of the COVID-19 pandemic on the Company's business and financial results; the Company's ability to create clinical distinction, compel surgeon adoption and earn market share; the Company's planned commercial launches, product introductions and product integration; when and whether the anticipated acquisition of EOS imaging, S.A. ultimately will close and the potential benefits and synergies thereof; and the Company's expectations with respect to future revenue and growth. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products in the Company's pipeline; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval for new products, or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement for procedures performed using the Company's products; the Company's ability to compete with other products and emerging new technologies; product liability exposure; patent infringement claims; changes to our financial results for the quarter and year ended December 31, 2020 due to the completion of financial closing procedures; and the impact of the COVID-19 on our business and the economy. The words "believe," "will," "should," "expect," "intend," "estimate," "look forward" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Preliminary Financial Results

This presentation includes financial results that are preliminary. The Company reports its financial results in accordance with U.S. generally accepted accounting principles. The expected financial results discussed in this presentation are preliminary and represent the most current information available to the Company's management, as financial closing procedures for the quarter ended December 31, 2020 are not yet complete. These estimates are not a comprehensive statement of the Company's financial results for the quarter and year ended December 31, 2020 and actual results may differ materially from these estimates as a result of the completion of normal quarter-end accounting procedures and adjustments, including the execution of the Company's internal control over financial reporting, the completion of the preparation and review of the Company's financial statements for the quarter ended December 31, 2020 and the subsequent occurrence or identification of events prior to the formal issuance of the fourth quarter and full year financial results.

2

THE NEW

Transformed organization to create

clinical distinction

Launching innovation that compels surgeon adoption and revitalizes the salesforce

Delivering industry leading U.S. organic revenue growth*

3	* Source: Spine-market.com, company reports

Q4 2020 SCORECARD*

The momentum we are building is STRONG

38%

75%

9th

YoY U.S. revenue growth

New product revenue contribution vs 48% in Q4 2019 and <10% in FY2018

Consecutive quarter of

double-digit YoY growth

14%

13%

1.9

YoY growth in

revenue per surgeon

YoY growth in average revenue per case; 36%

vs. Q4 of 2018

Average product categories sold per case

4

* Q4 2020 revenue and metrics are preliminary, unaudited, and subject to adjustment. See Disclaimer - Preliminary Financial Results.